EIK-002
Immunology/Inflammation (Undisclosed)
PreclinicalActive
Key Facts
Indication
Immunology/Inflammation (Undisclosed)
Phase
Preclinical
Status
Active
Company
About Eikon Therapeutics
Eikon Therapeutics' mission is to pioneer a new paradigm in drug discovery by directly observing the dynamic behavior of proteins in living cells, a field it terms 'dynamic biology.' The company has successfully built and scaled its proprietary platform, transitioned to a public company (NASDAQ: EIKN), and advanced a pipeline of five disclosed programs. Its strategy is to leverage its unique observational biology platform to identify and prosecute novel, high-value targets with the potential for first-in-class or best-in-class therapeutics.
View full company profile